Business Context and Reporting Period
Propanc Biopharma, Inc. filed this Form 8-K on September 3, 2019, to report the entry into a Material Definitive Agreement. The Company, incorporated in Delaware with principal offices in Australia, entered into a Securities Purchase Agreement with Auctus Fund LLC to secure financing.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard operating financial results. Key metrics include:
- Capital Raised: $550,000 in cash proceeds received on the Closing Date.
- Debt Instrument: A Convertible Promissory Note with a principal amount of $550,000.
- Interest Rate: 10% per annum (increasing to 24% per annum upon an Event of Default).
- Maturity Date: August 30, 2020.
- Equity Instruments: Three Common Stock Purchase Warrants issued alongside the Note.
- Warrant Coverage: Total of 975,000 shares of common stock across three warrants.
Material Changes and Terms
This filing represents a material change in the Company's capital structure and debt obligations. The transaction introduces the following specific terms:
- Conversion Discount: The Note is convertible into common stock at a price equal to 60% of the lowest closing bid price over the 10-day period preceding the conversion notice (a 40% discount).
- Beneficial Ownership Limit: Conversion is capped to prevent Auctus and affiliates from holding more than 4.99% of the issued and outstanding common stock.
- Prepayment Penalty: If the Company prepays the Note prior to August 13, 2020, it must pay 135% of the outstanding principal and interest. No prepayment right exists after this date.
- Warrant Exercise Prices:
- Warrant No. 1: 450,000 shares at $2.25 per share.
- Warrant No. 2: 300,000 shares at $3.33 per share.
- Warrant No. 3: 225,000 shares at $4.50 per share.
- Warrant Term: All warrants are exercisable for five years from the Closing Date.
Outlook, Risks, and Contingencies
The Company entered into a Registration Rights Agreement requiring the filing of a Form S-1 Registration Statement within 60 days of execution, with effectiveness required within 150 days. This covers shares issuable upon conversion of the Note and exercise of the Warrants.
Risks and Contingencies:
- Dilution Risk: The 40% conversion discount and the issuance of 975,000 warrant shares present significant potential dilution to existing shareholders.
- Liquidity Constraint: The prepayment penalty (135% of principal) restricts the Company's ability to retire this debt early without incurring a substantial premium.
- Default Risk: An Event of Default triggers a punitive interest rate of 24% per annum and allows the lender to declare the Note immediately due and payable.
Investor Verification Checklist
- Verify the current market price of Propanc Biopharma common stock to assess the immediate dilution impact of the 40% conversion discount.
- Confirm the Company's cash position post-transaction to evaluate its ability to service the 10% annual interest and avoid default.
- Review the status of the Form S-1 Registration Statement filing to ensure compliance with the 60-day filing and 150-day effectiveness deadlines.
- Assess the Company's ability to raise additional capital before the August 13, 2020 prepayment deadline to avoid the 35% prepayment penalty.